NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

IGC

IGC Pharma Inc

May 16 • 04:00PM ET

0.2993

Dollar change +0.0071
Percentage change 2.43	%

Healthcare • Biotechnology • USA • AMEX

Peers: CGC TLRY CRON ACB TVRD RVNC GNLN MNMD PHGE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.12	Insider Own	30.37%	Shs Outstand	78.20M	Perf Week	0.45%
Market Cap	23.85M	Forward P/E	-	EPS next Y	-0.10	Insider Trans	0.00%	Shs Float	55.48M	Perf Month	4.94%
Income	-8.81M	PEG	-	EPS next Q	-0.02	Inst Own	3.59%	Short Float	1.23%	Perf Quarter	-3.95%
Sales	1.24M	P/S	19.23	EPS this Y	54.55%	Inst Trans	0.21%	Short Ratio	2.33	Perf Half Y	-21.46%
Book/sh	0.08	P/B	3.74	EPS next Y	-5.00%	ROA	-86.63%	Short Interest	0.68M	Perf Year	-45.96%
Cash/sh	0.01	P/C	50.74	EPS next 5Y	18.29%	ROE	-115.06%	52W Range	0.25 - 0.62	Perf YTD	-10.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-13.79%	ROI	-137.53%	52W High	-51.73%	Beta	1.45
Dividend TTM	-	Quick Ratio	0.59	Sales past 5Y	10.84%	Gross Margin	4.77%	52W Low	18.53%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	1.15	EPS Y/Y TTM	50.63%	Oper. Margin	-663.75%	RSI (14)	52.25	Volatility	5.13% 5.50%
Employees	67	Debt/Eq	0.04	Sales Y/Y TTM	1.64%	Profit Margin	-712.70%	Recom	1.00	Target Price	3.88
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	73.09%	Payout	-	Rel Volume	0.81	Prev Close	0.29
Sales Surprise	25.98%	EPS Surprise	33.33%	Sales Q/Q	25.98%	Earnings	Feb 18 BMO	Avg Volume	293.97K	Price	0.30
SMA20	0.65%	SMA50	0.27%	SMA200	-12.97%	Trades		Volume	237,556	Change	2.43%

May-12-25 09:30AM	IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting (ACCESSWIRE)
Apr-24-25 09:30AM	IGC Pharma Welcomes Strategic Investment from Advisors (ACCESSWIRE) +6.73%
Apr-09-25 09:35AM	IGC Pharma expands CALMA trial with addition of Butler Hospital Program (TipRanks)
Mar-17-25 09:00AM	IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida (ACCESS Newswire)
Mar-12-25 09:00AM	IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" (ACCESS Newswire) +9.59%
09:00AM	Loading…
Mar-10-25 09:00AM	IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" (ACCESS Newswire) +6.46%
Mar-04-25 09:00AM	IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection (ACCESS Newswire)
Feb-21-25 09:25AM	IGC Pharma expands Holiby line with Longevity, Renew (TipRanks)
Feb-20-25 09:00AM	IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market (ACCESS Newswire)
Feb-18-25 08:30AM	IGC Pharma Reports Third Quarter Fiscal 2025 Results (ACCESS Newswire)
Feb-11-25 08:30AM	IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM) (ACCESS Newswire)
Jan-28-25 08:30AM	IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease (ACCESS Newswire)
Jan-21-25 08:30AM	IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor (ACCESS Newswire)
Jan-13-25 08:30AM	IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets (ACCESSWIRE)
Jan-08-25 08:30AM	IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy (ACCESSWIRE)
07:00PM	Loading…
Dec-19-24 07:00PM	IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 (ACCESSWIRE)
Dec-02-24 08:30AM	IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology (ACCESSWIRE)
Nov-25-24 08:30AM	IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment (Business Wire) +5.34%
Nov-14-24 08:30AM	IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline (ACCESSWIRE)
Nov-06-24 08:30AM	IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies (ACCESSWIRE)
Oct-17-24 08:30AM	IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 (ACCESSWIRE)
Oct-03-24 09:00AM	IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge (ACCESSWIRE) -6.10%
Sep-18-24 08:00AM	IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment (Business Wire)
Sep-04-24 08:00AM	IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease (Business Wire)
Aug-26-24 07:00PM	IGC Announces Results of its 2024 Annual Stockholders Meeting (Business Wire)
Aug-22-24 09:00AM	IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease (Business Wire) -7.56%
Aug-20-24 08:00AM	IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist (Business Wire) -7.62%
Aug-08-24 09:30PM	IGC Pharma Reports First Quarter Fiscal 2025 Results (Business Wire)
Jul-18-24 09:00AM	IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target (Business Wire) +5.71%
Jul-09-24 09:10AM	Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile (Business Wire)
09:00AM	Loading…
Jun-25-24 09:00AM	IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease (Business Wire) -8.10%
Jun-24-24 07:30PM	IGC Reports Financial Results for Fiscal Year Ended March 31, 2024 (Business Wire) -14.65%
Jun-18-24 09:00AM	IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets (Business Wire)
Jun-10-24 09:00AM	IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol (Business Wire)
May-28-24 09:00AM	IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1 (Business Wire)
May-21-24 02:00PM	IGC Pharma to Attend BIO International Convention 2024 (Business Wire)
May-09-24 08:45AM	6.7 Million Americans Live With Alzheimer's - IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings (News Direct)
Apr-16-24 07:00AM	IGC-AD1s Interim Phase 2 Data Show a Reduction in Alzheimers Agitation at Week Two (Business Wire) +10.66%
Apr-09-24 09:00AM	IGC Pharma Adds Advisor in Artificial Intelligence (Business Wire) -7.26%
Apr-03-24 09:00AM	IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research (News Direct) +19.59%
Mar-26-24 03:00PM	IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock (Business Wire)
Mar-20-24 11:00AM	IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimers Agitation (Business Wire) -8.91%
07:00AM	IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024 (Business Wire)
Mar-19-24 04:00PM	IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1 (News Direct) +11.56%
Mar-12-24 03:00PM	IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimers Pipeline (Business Wire)
Feb-28-24 01:00PM	Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model (Business Wire)
Feb-23-24 12:01PM	IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a "Buy" Recommendation and $3.00 Price Target (Business Wire) +12.22%
Feb-16-24 07:05PM	IGC Pharma Reports Third Quarter Fiscal 2024 Results (Business Wire)
Feb-01-24 09:20AM	IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model (Business Wire)
Jan-23-24 09:20AM	IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimers (Business Wire)
Jan-17-24 09:20AM	IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimers Trial (Business Wire)
Dec-19-23 09:20AM	Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimers (Business Wire) +8.31%
Dec-13-23 09:30AM	IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024 (Business Wire)
Dec-06-23 08:30AM	IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials (Business Wire)
Nov-21-23 08:30AM	IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives (Business Wire)
Nov-13-23 08:00AM	IGC Pharma Reports Second Quarter Fiscal 2024 Results (Business Wire)
Oct-19-23 03:30PM	IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy (Business Wire)
Aug-21-23 02:30PM	IGC Announces Results of its 2023 Annual Stockholders Meeting (Business Wire)
Aug-14-23 08:30AM	IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimers Candidate Through Phase 2 Clinical Trials (Business Wire)
Aug-02-23 08:30AM	IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico (Business Wire)
Jul-18-23 05:22AM	IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimers Association International Conference (Business Wire)
Jul-12-23 08:44AM	IGC Reports Financial Results for Fiscal Year Ended March 31, 2023 (Business Wire)
Jul-07-23 09:15AM	IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research (Business Wire) +22.68%
Jul-06-23 07:46AM	IGC Pharma Announces a $3 Million Private Placement of its Common Stock (Business Wire)
Jun-06-23 09:20AM	IGC Pharma Receives Notice of Allowance for Patent on Seizures (Business Wire)
Jun-05-23 08:30AM	IGC Pharmas Advisor and Inventor of Drug Candidate TGR-63 Receives Award (Business Wire) +6.67%
May-18-23 08:30AM	IGC Pharma to Present at LD Micro Invitational XIII (Newsfile)
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -6.92%
Apr-18-23 08:30AM	IGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & Hold 1x1 Meetings on Thursday, April 27, 2023 (ACCESSWIRE)
Mar-22-23 08:30AM	IGC Pharma to Attend Investor Summit (Newsfile)
Mar-20-23 08:45AM	IGC Announces Rebranding, Changes Name to IGC Pharma, Inc. (GlobeNewswire)
Feb-14-23 07:41PM	IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022 (GlobeNewswire)
Feb-08-23 08:30AM	IGC to be Featured in Feb. 10 Radius Research Investor Webinar (GlobeNewswire)
Jan-04-23 08:00AM	IGC Receives No Objection Letter from Health Canada (GlobeNewswire)
Dec-20-22 08:30AM	IGC Announces Updated Life Sciences Presentation (GlobeNewswire)
Dec-07-22 08:30AM	IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act (GlobeNewswire)
Dec-01-22 08:30AM	IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimers Disease (Business Wire) +7.11%
Nov-30-22 11:19AM	IGC to Present at the RHK 2022 Disruptive Growth Conference (GlobeNewswire) -7.50%
Nov-01-22 04:30PM	IGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022 (Business Wire) -6.52%
Sep-21-22 06:00AM	IGC Announces Issuance of Second Patent for the Treatment of Alzheimers Using THC (Business Wire)
Sep-12-22 07:00AM	IGC Announces Results of its 2022 Annual Stockholders Meeting (Business Wire)
Aug-08-22 06:00AM	IGC Reports Financial Results for the Quarter Ended June 30, 2022 (Business Wire) +5.47%
Jun-22-22 11:26PM	IGC Reports Financial Results for Fiscal Year Ended March 31, 2022 (Business Wire)
Jun-21-22 12:15AM	IGC Acquires Exclusive Rights for a Potential Alzheimers Drug Development Candidate (Business Wire) +6.60%
Jun-08-22 09:03PM	IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders (Business Wire) +93.35% -24.17%
Apr-18-22 05:28PM	India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits (Business Wire)
Mar-23-22 04:55PM	India Globalization Capital Appoints Claudia Grimaldi to its Board of Directors (Business Wire) +5.78% +10.47%
Feb-10-22 04:30PM	IGC Reports Financial Results for the December 31, 2021 Quarter (Business Wire) -6.42%
Jan-19-22 09:29AM	India Globalization Capital Appoints Former Congressman Jim Moran to Its Board of Directors (Business Wire)
Dec-14-21 09:25AM	Clinical Trial on Alzheimers Patients Indicates Positive Safety and Tolerability Data for IGCs THC-Based Investigational New Drug (Business Wire)
Dec-08-21 05:43PM	Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimers Patients (Business Wire)
Dec-02-21 09:32AM	Phase 1 Clinical Trial Data Indicate IGCs THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimers Patients (Business Wire)
Oct-29-21 10:09PM	IGC Reports Financial Results for the September 30, 2021 Quarter (Business Wire)
Oct-15-21 04:00PM	IGC Announces Results of its 2021 Annual Stockholders Meeting (Business Wire)
Sep-07-21 07:30PM	IGC Completes its Phase 1 Clinical Trial on Alzheimers Patients, Reports Safety and Tolerability (Business Wire)
Aug-11-21 08:00PM	IGC Reports Financial Results for the June 30, 2021, Quarter (Business Wire)
Jul-22-21 07:00AM	IGC Announces Issuance of Patent for the Treatment of Alzheimers Disease Using THC (Business Wire) +89.19%
Jun-23-21 06:50PM	IGC Completes the Final Cohort of Its Phase 1 Clinical Trial on Alzheimers Patients (Business Wire) +11.49%
Jun-14-21 06:00PM	IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021 (Business Wire) +8.05%
Jun-07-21 11:26PM	IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimers Patients (Business Wire) +21.58%

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moran James P	Director	Sep 25 '24	Buy	0.34	588,235	200,000	942,402	Sep 27 04:05 PM
PRINS RICHARD K	Director	Aug 12 '24	Proposed Sale	0.39	200,000	78,200		Aug 09 06:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IGC

IGC Pharma Inc

Upgrade your FINVIZ experience